Thai FDA reports over 52m-baht peptide haul on September 11

Thailand’s Food and Drug Administration (FDA) and Metropolitan Police Bureau announced on September 11, 2026 that they had seized unregistered peptide injection products and equipment worth more than 52 million baht from a house in Nonthaburi. The products were sold as Haus of peptide and advertised for weight loss, according to the Thai FDA’s announcement.

Thai health officials warned that the contents and manufacturing standards of unregistered injections could not be assured. Public Health Permanent Secretary Dr Somrerk Jeungsmarn said non-sterile injections could cause bloodstream infections that may be fatal.

Police trace Haus of peptide sales after parent’s complaint

The Metropolitan Police Bureau’s child and women’s welfare unit began investigating after a parent complained that their daughter had injected a Haus of peptide product and might be at risk.

Police traced advertisements to a social media account whose Thai name translates as “Hom reviews only quality products”. Investigators coordinated with the FDA after finding that the advertised injections had no drug registration numbers, leading to a search of a house in Sao Thong Hin subdistrict, Bang Yai district, Nonthaburi.

Police alleged that the sellers had operated for about a year, renting the house and employing migrant workers to pack orders for delivery by private couriers. Investigators said the operation dispatched an average of 100 boxes a day, priced at 2,900 baht each.

Authorities said they were taking action under the Drug Act 1967 for two alleged offences:

• Selling modern medicines without a licence, punishable by up to five years’ imprisonment and a fine of up to 10,000 baht.
• Selling unregistered medicines, punishable by up to three years’ imprisonment, a fine of up to 5,000 baht, or both.

Thai FDA warns over unknown ingredients and sterility

FDA secretary-general Supattra Boonserm urged the public and beauty treatment providers to avoid buying unregistered injections. Supattra said buyers could receive counterfeit products, products without the claimed active ingredient, or substances whose actual contents and production standards were unknown.

Supattra said the FDA had authorised medicines in this category after assessing their quality and safety. The lower price of an unregistered product did not make it a safe alternative, Supattra warned.

Somrerk said the Health Ministry and FDA had been monitoring and taking action against illegal imports and sales of injections promoted for weight loss. The relevant medicines include glucagon-like peptide-1 (GLP-1) receptor agonists, a class originally developed to treat type 2 diabetes.

Somrerk said these medicines require close medical assessment and supervision. The Nation previously reported on Thailand’s classification of injectable GLP-1 medicines as specially controlled drugs, requiring a doctor’s prescription.

Somrerk listed nausea, diarrhoea, vomiting, constipation, abdominal pain and bloating among potential gastrointestinal effects, with acute pancreatitis and acute kidney failure among the more serious complications.

Somrerk also warned that inappropriate use or stopping treatment without specialist supervision could lead to rapid weight regain, commonly called the yo-yo effect.

GLP-1 safety warnings need drug-specific context

Somrerk’s warning included depression and thoughts of self-harm, but the US Food and Drug Administration said on January 13, 2026 that its review found no increased risk of suicidal thoughts or behaviour with GLP-1 receptor agonists. The US regulator requested removal of that warning from affected medicines’ labels and said its clinical-trial analysis also found no increased risk of depression. 

Somrerk also raised thyroid cancer concerns. The US prescribing information for tirzepatide, marketed as Zepbound, states that thyroid C-cell tumours occurred in rats, while the risk in humans remains unknown. The medicine is contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. 

Somrerk additionally warned of fluid retention, joint pain and possible stimulation of cancer-cell growth in susceptible patients. 

February and September cases involve goods worth about 70 million baht

The FDA and Central Investigation Bureau announced an earlier crackdown on February 18, 2026 covering three operations in Bangkok, Nakhon Pathom and Ratchaburi. Authorities reported seizing more than 119,000 items worth approximately 17.94 million baht; the FDA’s account dates the searches to January and early February. 

Products in the earlier case carried labels or claims referring to tirzepatide, retatrutide, cagrilintide and tesamorelin. Sellers promoted effects ranging from appetite suppression, weight loss and fat burning to increased muscle mass and anti-ageing.

The FDA’s earlier investigation concerned unregistered products, so the names printed on their labels did not establish that the stated substances were present or that the contents matched the claimed quantities.

The February announcement and September Haus of peptide case represent two major enforcement operations publicised about seven months apart. The reported seizure valuations total roughly 70 million baht, with the September figure stated as more than 52 million baht.